Back to top
more

Insulet (PODD)

(Delayed Data from NSDQ)

$322.22 USD

322.22
1,108,987

-9.91 (-2.98%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $321.30 -0.92 (-0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Illumina (ILMN) Launches Initiative on Pathogen Sequencing

by Zacks Equity Research

Illumina (ILMN) introduces a new initiative to drive more equitable access to genomics globally.

Zacks Equity Research

Encompass Health (EHC) Opens Hospital to Boost Presence in Texas

by Zacks Equity Research

Encompass Health (EHC) opens an inpatient rehabilitation hospital in Prosper to address the diversified needs of the greater Dallas area residents. It marks EHC's 160th nationwide facility.

Zacks Equity Research

Prestige Consumer's (PBH) Brand Building, Innovation Aid Growth

by Zacks Equity Research

Prestige Consumer's (PBH) long-term brand-building efforts, efficient marketing, channel development and innovation help the company to continually hold a leading market share position.

Zacks Equity Research

QIAGEN (QGEN) Launches QIAcuity Kits and Software Update

by Zacks Equity Research

QIAGEN's (QGEN) new QIAcuity kits are likely to expand application areas and foster digital PCR adoption.

Zacks Equity Research

Here's Why Investors Should Buy Alcon (ALC) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about Alcon (ALC), backed by a competitive product portfolio and strong commercial execution.

Zacks Equity Research

IDEXX's (IDXX) Upcoming Launch to Detect Canine Leishmaniosis

by Zacks Equity Research

IDEXX (IDXX) expands the SNAP franchise with a comprehensive solution for detecting canine leishmaniosis.

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook Insulet (PODD)

by Zacks Equity Research

Insulet (PODD) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business and momentum in ProCyte One expansion.

Zacks Equity Research

Surging Earnings Estimates Signal Upside for Insulet (PODD) Stock

by Zacks Equity Research

Insulet (PODD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Chemed's (CHE) VITAS Performance Aids, Macro Issues Linger

by Zacks Equity Research

Chemed (CHE) believes Roto-Rooter is well-positioned for growth and anticipates continued expansion of the segment's market share.

Zacks Equity Research

How to Find Strong Buy Medical Stocks Using the Zacks Rank

by Zacks Equity Research

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.

Zacks Equity Research

Here's How Much a $1000 Investment in Insulet Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Zacks Equity Research

Insulet (PODD) Banks on Omnipod for Consistent Market Share Gain

by Zacks Equity Research

Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.

Zacks Equity Research

QIAGEN (QGEN) Launches Workflow to Boost Microbiome Research

by Zacks Equity Research

QIAGEN (QGEN) expands the Microbiome solutions portfolio with the launch of Microbiome WGS SeqSets.

Zacks Equity Research

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors remain optimistic about Tandem Diabetes (TNDM), backed by upcoming innovative launches, including Mobi and the new integrated CGM offering.

Sweta Killa headshot

5 Stocks That Powered S&P 500 ETF Last Week

by Sweta Killa

After entering correction territory in the last week of October, the S&P 500 Index staged a solid comeback in the first week of November.

Zacks Equity Research

Insulet (PODD) Q3 Earnings Beat, 2023 Sales Growth View Up

by Zacks Equity Research

Insulet's (PODD) third-quarter 2023 revenues increase year over year as a result of continued high demand for Omnipod 5.

Zacks Equity Research

Wall Street Analysts Think Insulet (PODD) Could Surge 53.28%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 53.3% upside potential for Insulet (PODD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Insulet (PODD) Just Overtook the 50-Day Moving Average

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?

Zacks Equity Research

QIAGEN's (QGEN) Molecular Diagnostics Gains Share, FX Woe Stays

by Zacks Equity Research

QIAGEN (QGEN) continues to see a very healthy conversion trend from the tuberculin skin test.

Zacks Equity Research

Teleflex (TFX) Q3 Earnings Top Estimates, 2023 Outlook Up

by Zacks Equity Research

Teleflex's (TFX) year-over-year revenue growth was driven by all global product categories in Q3.

Zacks Equity Research

Haemonetics (HAE) Q2 Earnings Top Estimates, 2024 View Up

by Zacks Equity Research

The robust volume growth and price benefits in the Plasma business driven by strong momentum in U.S. collections and price benefit Haemonetics' (HAE) fiscal second-quarter results.

Zacks Equity Research

Insulet (PODD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Envista (NVST) Q3 Earnings Miss Estimates, Gross Margin Down

by Zacks Equity Research

Envista's (NVST) Q3 performance is impacted by the negative impact of Russia and the weakness of higher-end specialty procedures in developed markets.

Shaun Pruitt headshot

3 Medical Products Stocks to Consider as Earnings Approach

by Shaun Pruitt

These top-rated Zacks Medical sector stocks are very attractive ahead of their quarterly reports on Thursday, November 2 with now looking like an ideal time to invest.